High prices for orphan drugs strain families, insurers
Consumer Corner January 22, 2017 Kaiser Health News 0
The orphan drug program overseen by the FDA is loaded with government incentives and has helped hundreds of thousands of patients feel better or even stay alive, but the program has opened the door to almost unlimited price tags and created incentives for drug makers to cash in, and to cash in repeatedly.
Hospital vaccine mandates
Jul 31, 2021 0
Pandemic fuels opioid crisis
Jul 31, 2021 0
Where do we stand on COVID?
Jul 11, 2021 0
No comments so far.
Be first to leave comment below.